Vaxart (VXRT) to Release Quarterly Earnings on Thursday

Vaxart (NASDAQ:VXRT - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Vaxart to post earnings of ($0.10) per share and revenue of $15.68 million for the quarter.

Vaxart Stock Up 4.2 %

NASDAQ:VXRT traded up $0.02 during mid-day trading on Friday, hitting $0.54. 1,030,977 shares of the stock traded hands, compared to its average volume of 2,373,316. The stock has a market capitalization of $122.63 million, a price-to-earnings ratio of -1.31 and a beta of 1.69. Vaxart has a 52 week low of $0.45 and a 52 week high of $1.41. The firm's 50 day moving average is $0.68 and its two-hundred day moving average is $0.72.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.